7l9m - Revision history

OCA at 15:41, 18 October 2023

OCA — Wed, 18 Oct 2023 15:41:34 GMT

←Older revision		Revision as of 15:41, 18 October 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[7l9m]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7L9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7L9M FirstGlance]. <br>		<table><tr><td colspan='2'>[[7l9m]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7L9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7L9M FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=XR4:N,N-[(1,19-dioxo-4,7,10,13,16-pentaoxanonadecane-1,19-diyl)di(piperidine-1,4-diyl)]bis(4-{[4-({3-[(tert-butylsulfonyl)amino]-4-chlorophenyl}amino)-5-methylpyrimidin-2-yl]amino}-2-fluorobenzamide)'>XR4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.45Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=XR4:N,N-[(1,19-dioxo-4,7,10,13,16-pentaoxanonadecane-1,19-diyl)di(piperidine-1,4-diyl)]bis(4-{[4-({3-[(tert-butylsulfonyl)amino]-4-chlorophenyl}amino)-5-methylpyrimidin-2-yl]amino}-2-fluorobenzamide)'>XR4</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7l9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7l9m OCA], [https://pdbe.org/7l9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7l9m RCSB], [https://www.ebi.ac.uk/pdbsum/7l9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7l9m ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7l9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7l9m OCA], [https://pdbe.org/7l9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7l9m RCSB], [https://www.ebi.ac.uk/pdbsum/7l9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7l9m ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein.<ref>PMID:12543779</ref> <ref>PMID:11733348</ref>	+	[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN] Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein.<ref>PMID:12543779</ref> <ref>PMID:11733348</ref>
	== Function ==		== Function ==
-	[[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Plays a role in a process governing chromosomal dynamics during mitosis (By similarity).	+	[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN] Plays a role in a process governing chromosomal dynamics during mitosis (By similarity).
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 7l9m" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 7l9m" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Bromodomain-containing protein 3D structures\|Bromodomain-containing protein 3D structures]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 03:47, 8 September 2022

OCA — Thu, 08 Sep 2022 03:47:41 GMT

←Older revision		Revision as of 03:47, 8 September 2022
Line 1:		Line 1:

	==Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083==		==Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083==
-	<StructureSection load='7l9m' size='340' side='right'caption='[[7l9m]]' scene=''>	+	<StructureSection load='7l9m' size='340' side='right'caption='[[7l9m]], [[Resolution\|resolution]] 1.45Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7L9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7L9M FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[7l9m]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7L9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7L9M FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7l9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7l9m OCA], [https://pdbe.org/7l9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7l9m RCSB], [https://www.ebi.ac.uk/pdbsum/7l9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7l9m ProSAT]</span></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=XR4:N,N-[(1,19-dioxo-4,7,10,13,16-pentaoxanonadecane-1,19-diyl)di(piperidine-1,4-diyl)]bis(4-{[4-({3-[(tert-butylsulfonyl)amino]-4-chlorophenyl}amino)-5-methylpyrimidin-2-yl]amino}-2-fluorobenzamide)'>XR4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7l9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7l9m OCA], [https://pdbe.org/7l9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7l9m RCSB], [https://www.ebi.ac.uk/pdbsum/7l9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7l9m ProSAT]</span></td></tr>
	</table>		</table>
		+	== Disease ==
		+	[[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein.<ref>PMID:12543779</ref> <ref>PMID:11733348</ref>
		+	== Function ==
		+	[[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Plays a role in a process governing chromosomal dynamics during mitosis (By similarity).
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Bromodomain and extraterminal domain (BET) proteins are important regulators of gene transcription and chromatin remodeling. BET family members BRD4 and BRDT are validated targets for cancer and male contraceptive drug development, respectively. Due to the high structural similarity of the acetyl-lysine binding sites, most reported inhibitors lack intra-BET selectivity. We surmised that protein-protein interactions induced by bivalent inhibitors may differ between BRD4 and BRDT, conferring an altered selectivity profile. Starting from nonselective monovalent inhibitors, we developed cell-active bivalent BET inhibitors with increased activity and selectivity for BRDT. X-ray crystallographic and solution studies revealed unique structural states of BRDT and BRD4 upon interaction with bivalent inhibitors. Varying spacer lengths and symmetric vs unsymmetric connections resulted in the same dimeric states, whereas different chemotypes induced different dimers. The findings indicate that the increased intra-BET selectivity of bivalent inhibitors is due to the differential plasticity of BET bromodomains upon inhibitor-induced dimerization.
		+
		+	Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.,Guan X, Cheryala N, Karim RM, Chan A, Berndt N, Qi J, Georg GI, Schonbrunn E J Med Chem. 2022 Jul 22. doi: 10.1021/acs.jmedchem.2c00453. PMID:35867655<ref>PMID:35867655</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 7l9m" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Karim MR]]		[[Category: Karim MR]]
	[[Category: Schonbrunn E]]		[[Category: Schonbrunn E]]

OCA at 11:02, 31 August 2022

OCA — Wed, 31 Aug 2022 11:02:06 GMT

←Older revision		Revision as of 11:02, 31 August 2022
Line 1:		Line 1:

	==Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083==		==Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083==
-	<StructureSection load='7l9m' size='340' side='right'caption='[[7l9m]]~~, [[Resolution\|resolution]] 1.45Å~~' scene=''>	+	<StructureSection load='7l9m' size='340' side='right'caption='[[7l9m]]' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>~~[[7l9m]] is a 2 chain structure.~~ Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7L9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7L9M FirstGlance]. <br>	+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7L9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7L9M FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=XR4:N,N-[(1,19-dioxo-4,7,10,13,16-pentaoxanonadecane-1,19-diyl)di(piperidine-1,4-diyl)]bis(4-{[4-({3-[(tert-butylsulfonyl)amino]-4-chlorophenyl}amino)-5-methylpyrimidin-2-yl]amino}-2-fluorobenzamide)'>XR4</scene></td></tr>	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7l9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7l9m OCA], [https://pdbe.org/7l9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7l9m RCSB], [https://www.ebi.ac.uk/pdbsum/7l9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7l9m ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7l9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7l9m OCA], [https://pdbe.org/7l9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7l9m RCSB], [https://www.ebi.ac.uk/pdbsum/7l9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7l9m ProSAT]</span></td></tr>	+
	</table>		</table>
-	== Disease ==
-	[[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein.<ref>PMID:12543779</ref> <ref>PMID:11733348</ref>
-	== Function ==
-	[[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Plays a role in a process governing chromosomal dynamics during mitosis (By similarity).
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	Bromodomain and extraterminal domain (BET) proteins are important regulators of gene transcription and chromatin remodeling. BET family members BRD4 and BRDT are validated targets for cancer and male contraceptive drug development, respectively. Due to the high structural similarity of the acetyl-lysine binding sites, most reported inhibitors lack intra-BET selectivity. We surmised that protein-protein interactions induced by bivalent inhibitors may differ between BRD4 and BRDT, conferring an altered selectivity profile. Starting from nonselective monovalent inhibitors, we developed cell-active bivalent BET inhibitors with increased activity and selectivity for BRDT. X-ray crystallographic and solution studies revealed unique structural states of BRDT and BRD4 upon interaction with bivalent inhibitors. Varying spacer lengths and symmetric vs unsymmetric connections resulted in the same dimeric states, whereas different chemotypes induced different dimers. The findings indicate that the increased intra-BET selectivity of bivalent inhibitors is due to the differential plasticity of BET bromodomains upon inhibitor-induced dimerization.
-
-	Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.,Guan X, Cheryala N, Karim RM, Chan A, Berndt N, Qi J, Georg GI, Schonbrunn E J Med Chem. 2022 Jul 22. doi: 10.1021/acs.jmedchem.2c00453. PMID:35867655<ref>PMID:35867655</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 7l9m" style="background-color:#fffaf0;"></div>
-	== References ==
-	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Karim~~, M R~~]]	+	[[Category: Karim MR]]
-	[[Category: Schonbrunn, E]]	+	[[Category: Schonbrunn E]]
-	~~[[Category: Bet]]~~	+
-	~~[[Category: Dual brd-kinase inhibitor]]~~	+
-	~~[[Category: Erk5]]~~	+
-	~~[[Category: Gene regulation]]~~	+
-	~~[[Category: Transcription-transcription inhibitor complex~~]]	+

OCA at 04:59, 3 August 2022

OCA — Wed, 03 Aug 2022 04:59:01 GMT

←Older revision		Revision as of 04:59, 3 August 2022
Line 1:		Line 1:

	==Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083==		==Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083==
-	<StructureSection load='7l9m' size='340' side='right'caption='[[7l9m]]' scene=''>	+	<StructureSection load='7l9m' size='340' side='right'caption='[[7l9m]], [[Resolution\|resolution]] 1.45Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7L9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7L9M FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[7l9m]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7L9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7L9M FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7l9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7l9m OCA], [https://pdbe.org/7l9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7l9m RCSB], [https://www.ebi.ac.uk/pdbsum/7l9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7l9m ProSAT]</span></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=XR4:N,N-[(1,19-dioxo-4,7,10,13,16-pentaoxanonadecane-1,19-diyl)di(piperidine-1,4-diyl)]bis(4-{[4-({3-[(tert-butylsulfonyl)amino]-4-chlorophenyl}amino)-5-methylpyrimidin-2-yl]amino}-2-fluorobenzamide)'>XR4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7l9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7l9m OCA], [https://pdbe.org/7l9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7l9m RCSB], [https://www.ebi.ac.uk/pdbsum/7l9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7l9m ProSAT]</span></td></tr>
	</table>		</table>
		+	== Disease ==
		+	[[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein.<ref>PMID:12543779</ref> <ref>PMID:11733348</ref>
		+	== Function ==
		+	[[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Plays a role in a process governing chromosomal dynamics during mitosis (By similarity).
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Bromodomain and extraterminal domain (BET) proteins are important regulators of gene transcription and chromatin remodeling. BET family members BRD4 and BRDT are validated targets for cancer and male contraceptive drug development, respectively. Due to the high structural similarity of the acetyl-lysine binding sites, most reported inhibitors lack intra-BET selectivity. We surmised that protein-protein interactions induced by bivalent inhibitors may differ between BRD4 and BRDT, conferring an altered selectivity profile. Starting from nonselective monovalent inhibitors, we developed cell-active bivalent BET inhibitors with increased activity and selectivity for BRDT. X-ray crystallographic and solution studies revealed unique structural states of BRDT and BRD4 upon interaction with bivalent inhibitors. Varying spacer lengths and symmetric vs unsymmetric connections resulted in the same dimeric states, whereas different chemotypes induced different dimers. The findings indicate that the increased intra-BET selectivity of bivalent inhibitors is due to the differential plasticity of BET bromodomains upon inhibitor-induced dimerization.
		+
		+	Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.,Guan X, Cheryala N, Karim RM, Chan A, Berndt N, Qi J, Georg GI, Schonbrunn E J Med Chem. 2022 Jul 22. doi: 10.1021/acs.jmedchem.2c00453. PMID:35867655<ref>PMID:35867655</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 7l9m" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Karim MR]]	+	[[Category: Karim, M R]]
-	[[Category: Schonbrunn E]]	+	[[Category: Schonbrunn, E]]
		+	[[Category: Bet]]
		+	[[Category: Dual brd-kinase inhibitor]]
		+	[[Category: Erk5]]
		+	[[Category: Gene regulation]]
		+	[[Category: Transcription-transcription inhibitor complex]]

OCA at 09:56, 12 January 2022

OCA — Wed, 12 Jan 2022 09:56:41 GMT

←Older revision		Revision as of 09:56, 12 January 2022
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry 7l9m is ON HOLD until Jan 04 2023~~	+	==Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083==
-		+	<StructureSection load='7l9m' size='340' side='right'caption='[[7l9m]]' scene=''>
-	~~Authors: Karim, M.R., Schonbrunn, E.~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7L9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7L9M FirstGlance]. <br>
-	~~Description:~~ Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7l9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7l9m OCA], [https://pdbe.org/7l9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7l9m RCSB], [https://www.ebi.ac.uk/pdbsum/7l9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7l9m ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	</table>
-	[[Category: Karim~~, M.R~~]]	+	__TOC__
-	[[Category: Schonbrunn, E]]	+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Karim MR]]
		+	[[Category: Schonbrunn E]]

OCA at 15:28, 15 December 2021

OCA — Wed, 15 Dec 2021 15:28:12 GMT

←Older revision		Revision as of 15:28, 15 December 2021
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 7l9m is ON HOLD until ~~Dec~~ 04 ~~2022~~	+	The entry 7l9m is ON HOLD until Jan 04 2023

	Authors: Karim, M.R., Schonbrunn, E.		Authors: Karim, M.R., Schonbrunn, E.

OCA at 08:45, 14 July 2021

OCA — Wed, 14 Jul 2021 08:45:02 GMT

←Older revision		Revision as of 08:45, 14 July 2021
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 7l9m is ON HOLD until ~~Jul~~ 04 2022	+	The entry 7l9m is ON HOLD until Dec 04 2022

	Authors: Karim, M.R., Schonbrunn, E.		Authors: Karim, M.R., Schonbrunn, E.

OCA: Protected "7l9m" [edit=sysop:move=sysop]

OCA — Wed, 20 Jan 2021 06:53:18 GMT

Protected "7l9m" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:53, 20 January 2021

OCA: New page: '''Unreleased structure''' The entry 7l9m is ON HOLD until Jul 04 2022 Authors: Karim, M.R., Schonbrunn, E. Description: Crystal structure of the first bromodomain (BD1) of human BRD4 ...

OCA — Wed, 20 Jan 2021 06:53:17 GMT

New page: '''Unreleased structure''' The entry 7l9m is ON HOLD until Jul 04 2022 Authors: Karim, M.R., Schonbrunn, E. Description: Crystal structure of the first bromodomain (BD1) of human BRD4 ...

New page

'''Unreleased structure'''

The entry 7l9m is ON HOLD until Jul 04 2022

Authors: Karim, M.R., Schonbrunn, E.

Description: Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083
[[Category: Unreleased Structures]]
[[Category: Karim, M.R]]
[[Category: Schonbrunn, E]]